Telormedix TMX-101 Commences Clinical Trial for Bladder Cancer  
6/14/2010 6:46:52 AM

BIOGGIO, Switzerland--(BUSINESS WIRE)--Telormedix, a clinical stage biopharmaceutical company focused on targeted immunity in the treatment of cancer and other diseases, today announced the start of a Phase I/II clinical study of TMX-101 for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC). TMX-101 is an immunotherapeutic compound and Telormedix has already recruited the first patients for this clinical study.